CCO Neuroscience Podcast

View Details

Novel C5 inhibitors are reshaping individualized care for generalized myasthenia gravis. Listen in to learn from Drs Muppidi, Narayanaswami, Kaminski, and Paul about persistent needs in gMG care, clinical differences among C5 inhibitors, and practical considerations for matching treatment decisions to patient goals, access, safety, and long-term adherence.

Presenters:

Srikanth Muppidi, MD
Clinical Professor
Department of Neurology and Neurological Sciences
Stanford University
Stanford, California

Pushpa Narayanaswami, MD, FAAN
Professor of Clinical Neurology
Harvard Medical School
Vice Chair, Clinical Operations
Department of Neurology
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Henry J. Kaminski, MD
Jeffrey Lieberman Professor of Neurosciences
Professor of Neurology, Pharmacology & Physiology
George Washington University
Principal Investigator, MGNet
Rare Disease Clinical Research Consortium
Washington, DC

Pritikanta Paul, MD
Assistant Professor of Neurology
University of California, San Francisco
Co-Director, MG Clinic
San Francisco, California

Link to full program:
https://bit.ly/4aXq3Ce

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

Multiple sclerosis care is evolving fast, from what current AAN guidance emphasizes to what’s emerging in the treatment pipeline. In this episode, Patricia K. Coyle, MD, FAAN, FANA, reviews practical, patient-centered principles for MS management, including shared decision-making, realistic expectations, adherence, monitoring, and optimizing comorbidities and lifestyle factors. She also explains when to reassess and potentially switch therapy based on relapses, disability progression, and MRI activity, and highlights pipeline advances such as CNS-penetrant BTK inhibitors and other investigational approaches.

Presenters:
Patricia K. Coyle, MD, FAAN, FANA
Distinguished Professor of Neurology
Vice Chair for Academic Affairs
Department of Neurology
Stony Brook Renaissance School of Medicine
Director, MS Comprehensive Care Center
Stony Brook, New York

Link to full program:
https://bit.ly/4dhvLAL

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

Wondering what is coming next in MS care beyond today’s disease-modifying therapies? This episode spotlights CNS-penetrant oral BTK inhibitors and the fast-moving pipeline targeting neuroinflammation, immune reset, and future CNS repair, then brings it to life with a real patient case that tests treatment selection and the decision to switch therapy. Led by Patricia K. Coyle, MD, FAAN, FANA, it is a practical listen for healthcare professionals who want a clear sense of where MS treatment is heading and why it matters now.

Presenters:

Patricia K. Coyle, MD, FAAN, FANA
Distinguished Professor of Neurology
Vice Chair for Academic Affairs
Department of Neurology
Stony Brook Renaissance School of Medicine
Director, MS Comprehensive Care Center
Stony Brook, New York

Link to full program:
https://bit.ly/4sau7px

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

Multiple sclerosis (MS) is increasingly understood as a spectrum in which relapsing activity and progression can overlap, creating a need for smart, individualized use of disease-modifying therapies. Listen in to learn from Patricia K. Coyle, MD, FAAN, FANA, for a practical review of today’s MS DMT options, with a focus on high-efficacy monoclonal antibodies such as anti-CD20 therapies, how healthcare professionals think about progression concepts like PIRA and RAW, and what emerging trial designs like OCTOPUS may mean for improving treatment options in progressive MS.

Presenter:

Link to full program:
https://bit.ly/3PdRks4

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

In this podcast episode, Dr Jonathan Meyer answers additional questions from learners at our Psychopharmacology Update conference. Questions explore other disease states where psychosis can occur, practical considerations around special populations, tolerability, drug combinations, and the potential future of muscarinic-based therapies. For additional activities in this program including a ClinicalThought commentary, a CME/CE/CPE certified on-demand webcast and a downloadable slideset, go to: https://bit.ly/4qjcYcj

Faculty:

Jonathan M. Meyer, MD, DLFAPA
Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Senior Academic Adviser
California Department of State Hospitals
San Diego, California

Get access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

In this episode of “Cognitive Conversations,” expert faculty discuss breaking data presentations from the 2026 Clinical Trials on Alzheimer’s Disease conference held in San Diego, California, from December 1-4, 2025, and their implications for clinical practice.

Topics covered include:

Evoke and evoke+ phase III trials of semaglutide
Subcutaneous lecanemab as initiation and maintenance treatment
Blood-based biomarker assays
Trontinemab and other brain shuttles
Tau targeting therapies in development
Preventive impact of BCG and herpes zoster vaccination

This podcast episode is part of the CME/CE-accredited program, “Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages,” supported by an educational grant from Novo Nordisk.

Faculty:

Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, and Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
University of Rochester School of Medicine and Dentistry
Rochester, New York

Vijay K. Ramanan, MD, PhD
Consultant and Associate Professor
Director, Alzheimer’s Disease Treatment Clinic
Department of Neurology
Mayo Clinic
Rochester, Minnesota

Link to obtain CME/CE credit:
https://bit.ly/4999otE

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

In this podcast episode, epilepsy specialists Danielle Becker, MD, MS, FAES, and Sarah Weatherspoon, MD, discuss the personalization of the most recently available epilepsy rescue treatments for younger kids and their implementation by the patient care team.

Faculty:

Danielle Becker, MD, MS, FAES
Division Director of Epilepsy
Associate Professor of Neurology
The Ohio State University Wexner Medical Center
Columbus, Ohio

Sarah Weatherspoon, MD
Associate Chief of Child Neurology
Tuberous Sclerosis Center of Excellence, Neurology Co-Director
Le Bonheur Children's Hospital
University of Tennessee Health Science Center
Memphis, Tennessee

Resources mentioned in this episode:

Epilepsy Foundation Seizure Action Plan Toolkit
CDC Managing Epilepsy Well (MEW) Network

Link to Brain Health Hub with additional educational activities:
https://bit.ly/3Y12Isx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

View Details

In this episode, Alireza Atri, MD, PhD, discusses his approach to patient conversations on brain health and provides advice to healthcare professionals practicing in community neurology settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.

Faculty:

Alireza Atri, MD, PhD
Chief Medical Officer, Banner Research
Phoenix, Tucson and Sun City, Arizona
Director, Banner Sun Health Research Institute
Sun City, Arizona

Robin Martinez
Patient Advocate
Coordinator of Online Communities
Website Administration
Smart Patients Inc.
Denver, Colorado

Resources mentioned in this episode:

Alzheimer’s Association: DETeCD-ADRD Clinical Practice Guidelines for Specialty Care
https://bit.ly/4kqtYt5
American Geriatrics Society: 2023 Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
https://bit.ly/44zN8qG
MoCA (Montreal Cognitive Assessment) : [Link to: https://mocacognition.com/]

Link to obtain CME/CE credit:
https://bit.ly/44khuP5

Link to Brain Health Hub with additional educational activities:
https://bit.ly/4kziu6T

View Details

| In this episode, dementia expert Anton Porsteinsson, MD, discusses his approach to conversations on brain health with patients and provides guidance for HCPs practicing in community psychiatry settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.Faculty:Anton P. Porsteinsson, MD William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and MedicineDirector, Alzheimer’s Disease Care, Research and Education Program (AD-CARE)University of Rochester School of Medicine and DentistryRochester, New YorkRobin MartinezPatient AdvocateCoordinator of Online CommunitiesWebsite AdministrationSmart Patients Inc.Denver, ColoradoResources mentioned in this episode:* Mini Mental State Examination (MMSE) [Link to: https://www.psychdb.com/_media/mmse.] * Mini-Cog (quick dementia screening test) [Link to: https://mini-cog.com/] * MoCA (Montreal Cognitive Assessment) : [Link to: https://mocacognition.com/] * Alzheimer’s Association Local Chapters [Link to:https://www.alz.org/chapter-search] * Local Department of Aging [Link to : https://www.thecountyoffice.com/department-of-aging/]

Link to obtain CME/CE credit: https://bit.ly/3IAbyc7Link to Brain Health Hub with additional educational activities: https://bit.ly/40Jgth4 |

View Details

In this episode, Genevieve Neal-Perry, MD, PhD, discusses her approach to conversations on brain health with her patients in obstetrics and gynecology settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.

Faculty:

Genevieve Neal-Perry, MD, PhD
Robert A. Ross Distinguished Professor
Chair of Obstetrics and Gynecology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Robin Martinez
Patient Advocate
Coordinator of Online Communities
Website Administration
Smart Patients Inc.
Denver, Colorado

Resources mentioned in this episode:

Smart Patients, an online community for patients and their families [Link to: https://www.smartpatients.com/]

Link to obtain CME/CE credit:
https://bit.ly/4lH4BEt

Link to Brain Health Hub with additional educational activities:
https://bit.ly/4nJrgSG

View Details

In this episode, Pierre N. Tariot, MD, discusses his approach to conversations on brain health with his patients and their family members in primary care settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.

Faculty:
Pierre N. Tariot, MD
Director
Banner Alzheimer's Institute
Research Professor of Psychiatry
University of Arizona College of Medicine
Phoenix, Arizona

Robin Martinez
Patient Advocate
Coordinator of Online Communities
Website Administration
Smart Patients Inc.
Denver, Colorado

Resources mentioned in this episode:

Banner Alzheimer Institute
ECHO (Extension for Community Healthcare Outcomes)
MoCA (Montreal Cognitive Assessment)
Mini-Cog (quick dementia screening test)
FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease
Lancet Commission: Dementia Prevention, Intervention, and Care 2024

Link to obtain CME/CE credit:
https://bit.ly/4kk1vFs

Link to Brain Health Hub with additional educational activities:
https://bit.ly/3H4hoSl

View Details

In this episode, Susan Scanland, MSN, CRNP, GNP-BC, CDP, discusses her approach to conversations on brain health with her patients and their family members in clinical practice as a gerontological nurse practitioner, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.

Faculty:

Susan Scanland, MSN, CRNP, GNP-BC, CDP
CEO & Founder
Dementia Connection LLC
Clarks Summit, Pennsylvania
Robin Martinez
Patient Advocate
Coordinator of Online Communities
Website Administration
Smart Patients Inc.
Denver, Colorado

Resources mentioned in this episode:

Alzheimer’s Association: 2025 Alzheimer’s Disease Facts and Figures
Lancet Commission: Dementia Prevention, Intervention, and Care 2024
American Geriatrics Society: 2023 Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
Alzheimer’s Association: DETeCD-ADRD Clinical Practice Guidelines for Primary Care
Clinical Care Options: Integrating Brain Health Discussions Into Your Daily Routine

Link to obtain CME/CE credit:
https://bit.ly/4mqHoaS

Link to Brain Health Hub with additional educational activities:
https://bit.ly/3H4hoSl

View Details

Listen in as Cristina Mussini, MD; Martin Witzenrath, MD, FERS; and Michele Bartoletti, MD, PhD, discuss best practices in managing people who are immunocompromised with COVID-19 in the hospital setting, including:

COVID-19 burden among this population
Initial workup to assess disease severity
Summary of COVID-19 guideline recommendations
A detailed patient case to illustrate key takeaways

Presenters:

Michele Bartoletti, MD, PhD
Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy

Cristina Mussini, MD
Full Professor of Infectious Diseases
Chief of the Department of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Martin Witzenrath, MD, FERS
Medical Director
Charite Centrum 12
Internal Medicine & Dermatology
Professor and Chair for Respiratory Medicine and Critical Care
Department of Infectious Disease, Respiratory Medicine and Critical Care
Charite Campus Mitte/Campus Virchow Klinikum/Campus Benamin Franklin
Charite – University of Berlin
Berlin, Germany

Link to full program:
https://bit.ly/4fs7Hcb

Downloadable slides:
https://bit.ly/4imCRU5

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

View Details

In this episode, Dr Robert Cotes and Dr David Goldsmith discuss their clinical experience with long-acting injectable antipsychotic treatments in the Grady Health System, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making.

Presenters:

Robert O. Cotes, MD, DFAPA
Associate Professor and Distinguished Physician
Director, Clinical & Research Program for Psychosis at Grady Health System
Director, Project ARROW at Grady Health System
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

David R. Goldsmith, MD, MSc
Associate Professor
Director, Inflammation, Motivation, and Negative Symptoms of Schizophrenia (InMotioNSS) Lab
Co-Director, Clinical & Research Program for Psychosis at Grady Health System
Director, PSTAR Clinic at Grady Memorial Hospital
Faculty, Emory Behavioral Immunology Program
Co-Director, Psychiatry Residency Research Track
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

This content is part of an online CME program supported by educational grants from Indivior Inc.; Otsuka America Pharmaceutical, Inc. and Lundbeck; and Teva Pharmaceuticals.

Link to full program: https://bit.ly/414XkY4

View Details

In this episode, David N. Lieberman, MD, PhD, and Eric Marsh, MD, PhD, discuss recent updates relevant to the treatment of Rett syndrome, including:

The recently updated Comprehensive Care Guidelines from the International Rett Syndrome Foundation, available at rettsyndrome.org
Ongoing collection and analysis of longitudinal data within the Rett Syndrome Natural History Study
Efficacy and safety data from the double-blind, placebo-controlled phase III registrational LAVENDER trial evaluating oral trofinetide, a small molecule analogue of insulin-like growth factor 1
Topline results from phase III AVATAR and EXCELLENCE trials of the sigma-1 receptor agonist blarcamesine
Several early ongoing gene therapy trials

Dr Lieberman and Dr Marsh complement this informative update with wisdom from their own clinical experience to provide a full picture of current treatment and management options available to patients with Rett syndrome.

Presenters:

David N. Lieberman, MD, PhD
Director, Comprehensive Rett Syndrome Clinic
Department of Neurology
Boston Children's Hospital
Boston, Massachusetts

Eric Marsh, MD PhD
Clinical Director, Orphan Disease Center
Director (MPI), CHOP/Penn IDDRC
Professor, Departments of Neurology and Pediatrics
Division of Neurology
Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

This content is part of an online CME program in partnership with the International Rett Syndrome Foundation and supported by an educational grant from Acadia Pharmaceuticals. Link to full program:
https://bit.ly/4fJRRL0

View Details

Link to CME: Claim Credit - https://bit.ly/3OByCaE

In this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers:

How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settings
The role of antiseizure medications in DEE treatment management
The nonpharmacological treatment options available to patients with DEEs
The emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s disease
Results from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequency
The future of soticlestat as a treatment option for pediatric patients with DEEs

Presenters:

Jonathan J. Halford, MD
Professor
Director, Translational Research Unit
Department of Neurology
Medical University of South Carolina
Charleston, SC

Cecil Hahn, MD, MPH, FRCPC
Professor
Pediatric Epileptologist
University of Toronto
Toronto, Ontario, Canada

Content based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Link to full program:
https://bit.ly/45UUpQy

View Details

Link to CME: Claim Credit - https://bit.ly/3wbVkA1

In this episode, Drs. Halford and White discuss the emerging role of brain cholesterol in the development and potential treatment of neurological diseases like epilepsy or Alzheimer and Huntington diseases. The full episode covers:

Overview of brain cholesterol and its function in the body
Pathogenesis potential for certain diseases via brain cholesterol
Emerging research on a cholesterol synthase inhibitor as a novel therapy
The future of soticlestat as a potential treatment option for pediatric epilepsies—Lennox-Gastaut syndrome and Dravet syndrome—and other neurological diseases

Presenters:

Jonathan J. Halford, MD
Professor
Director, Translational Research Unit
Department of Neurology
Medical University of South Carolina
Charleston, SC

H. Steve White, PhD
Professor, Department of Pharmacy
Co-Director, Center for Epilepsy Drug Discovery
School of Pharmacy
University of Washington
Seattle, Washington

View Details

In this episode, Drs. Sabbagh and Isaacson discuss how to best approach Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in clinical practice, including accurately diagnosing patients and optimizing treatment in terms of patient preferences and reimbursement options. The full episode covers:

Defining AD and MCI and their clinical presentation
How to diagnose AD vs MCI
Reimbursement landscape for current diagnosing and monitoring tools
Precision medicine’s evolving role in diagnosing and treating patients with AD and/or MCI

Presenters:

Marwan Sabbagh, MD
Professor of Neurology
Alzheimer’s and Memory Disorders Division
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona

Richard Isaacson MD
Director of the Institute for Neurodegenerative Diseases
Florida

View Details

The treatment landscape of major depression is increasingly shifting from monoaminergic agents to agents that modulate glutamate and GABA. Healthcare professionals need to stay up to date and educated on these changes in order to discuss the most current treatment options with their patients. In this podcast episode, we interview Dr Anita Clayton, a clinician researcher who has been involved in some of the clinical trials for these novel glutamatergic and GABAergic medications, and ask her key questions about mechanism of action and clinical application. Listeners will come away from this podcast episode more informed and more excited for the future of major depression care.

Presenters:

Anita Clayton, MD
David C. Wilson Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor of Clinical Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

This podcast episode is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.

Link to full program:
https://bit.ly/3YdPMPa

View Details

Rett syndrome is a rare but severe neurodevelopmental disorder, and current treatment approaches primarily focus on symptom management and supportive care. However, recent clinical developments are providing hope for a changing treatment landscape. In this podcast episode, experts in Rett syndrome David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, discuss trofinetide and blarcamesine, 2 agents in late-stage clinical trials as treatment options for Rett syndrome. Throughout their conversation, Drs Lieberman and Neul review the pivotal LAVENDER, DAFFODIL, AVATAR, and EXCELLENCE trials, including information on the safety and efficacy profiles of trofinetide and blarcamesine. The experts end their discussion with a conversation about the potential roles of ketamine and gene therapy in the management of Rett syndrome.

Presenters:

David N. Lieberman, MD, PhD
Instructor
Department of Neurology
Harvard Medical School
Attending Physician
Child Neurology
Boston Children’s Hospital
Boston, Massachusetts

Jeffrey Neul, MD, PhD
Director
Pediatrics
Vanderbilt University Medical Center
Nashville, Tennessee

This activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.

To claim CME/CE credit for this podcast, complete the posttest here:
bit.ly/3JR4qq5.

For additional activities in this program, visit
bit.ly/3JR4qq5

View Details

In this podcast episode, Leslie Citrome, MD, MPH, and Adam Lowy, MD, share a wealth of knowledge about long-acting injectable (LAI) antipsychotics. Their conversation begins with an overview of the pharmacokinetic profiles of LAI antipsychotics and how they differ from their oral counterparts, as well as injection intervals available with current formulations. The experts also discuss the clinical utility of LAI antipsychotics in psychiatry practice, highlighting their role in assuring medication adherence and their application in both first- and later-episode psychosis. Finally, Drs Citrome and Lowy hit on practical aspects of incorporating LAI antipsychotics into patient care: communicating with patients to dispel myths and stigma surrounding injectable medications, identifying injection resources in your medical community, and strategies to navigate insurance barriers.

Throughout the podcast, Drs Citrome and Lowy reference several links to outside sources that can provide valuable education on LAI antipsychotics. Those links are listed below for your convenience.

Administering LAI Into Dorsal Gluteal Site:
https://bit.ly/3XjSm5a

Administering LAI Into Deltoid Site:
https://bit.ly/3Xlyq1L

Administering LAI Into Abdominal Site:
https://bit.ly/3wgGJ2Z

Presenters:

Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Adam Lowy, MD
Staff Psychiatrist
Ellenhorn
Los Angeles, California

This activity is supported by educational funding provided byOtsuka America Pharmaceutical, Inc. and Lundbeck.

For additional activities in this program, visit:
https://bit.ly/3iM0HiP

View Details

In this podcast episode, experts in Rett syndrome, David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, provide a comprehensive overview of Rett syndrome (RTT), a rare but severe neurodevelopmental disorder. They begin with a discussion on the clinical characteristics and typical disease progression of RTT before diving into the various genetic markers and how they may, or may not, be used in the diagnosis and prognosis. Finally, the experts ponder the future of RTT diagnoses, touching upon how we might identify RTT and intervene earlier, potential utilization of biomarkers, and the role of measurement-based care.

Presenters:

David N. Lieberman MD, PhD
Instructor
Department of Neurology
Harvard Medical School
Attending Physician
Child Neurology
Boston Children's Hospital
Boston, Massachusetts

Jeffrey Neul MD, PhD
Director
Pediatrics
Vanderbilt University Medical Center
Nashville, Tennessee

This activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.

To claim CME/CE credit for this podcast, complete the posttest here:
https://bit.ly/3WjtMjA

For additional activities in this program, visit:
https://bit.ly/3kfAn0U

View Details

In this podcast episode, epileptologists Aatif Husain, MD, and John Stern, MD, have a conversation about rescue therapies and how they fit into the spectrum of epilepsy management. Their discussion begins with sharing what they consider the utility of rescue therapies to be in the overall spectrum of epilepsy. As the conversation goes on, they address the role of rescue therapies in more specific patient populations, such as the newly diagnosed patient, a patient experiencing seizure clusters, and patients who may be experiencing either very few or relatively many breakthrough seizure events. In all scenarios, the experts relate the use of rescue therapies as “insurance”—hoping that the agents don’t have to be used, but having them available as coverage in the worst-case scenario. The podcast goes on to discuss rescue therapies in terms of available routes and mechanisms of action and practical strategies for talking to patients about these agents. Rounding out the episode, Drs Husain and Stern express their hopes for future developments in epilepsy management.

Presenters:

Aatif Husain, MD
Professor
Division of Epilepsy, Sleep and Clinical Neurophysiology
Department of Neurology
Duke University Medical Center
Durham, North Carolina

John Stern, MD
Professor
Neurology
Geffen School of Medicine, UCLA
Director
Epilepsy Clinical Program
UCLA Department of Neurology
Los Angeles, California

This content is based on a CE/CME program supported by an independent educational grant from Neurelis, Inc.

For additional activities in this program, visit
https://bit.ly/3GiLlu4.

View Details

In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson’s disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.

Presenters:

Marwan Sabbagh, MD, FAAN
Professor of Neurology
Alzheimer's and Memory Disorders Division
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona

Marta San Luciano, MD, MS, FAAN
Associate Professor of Neurology
University of California, San Francisco
Attending Neurologist
Neurology/Movement Disorders and Neuromodulation Center
University of California, San Francisco Medical Center
San Francisco, California

This content is based on a CE/CME program supported by an independent educational grant from Acadia Pharmaceuticals, Inc.

For additional activities in this program, visit
http://bit.ly/3tPMqnr

View Details

In this episode, Christoph U. Correll, MD, and John M. Kane, MD, discuss the various etiologies of tardive dyskinesia (TD). Although most healthcare professionals are aware of the risk for TD that comes with first- and second-generation antipsychotic use, there is less awareness around other modifiable and unmodifiable factors that increase risk for TD development. Some modifiable risks include metoclopramide use, anticholinergic use, and substance use disorder; unmodifiable risks include older age and female sex. The doctors agree that, regardless of the level of risk, careful documentation and evaluation should be conducted with patients to detect TD early—should it develop. Their conversation rounds out with considerations for treatment approaches and clinical pearls garnered from years in practice.

Presenters:
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor of Child and Adolescent Psychiatry
Charité – Universitätsmedizin Berlin
Berlin, Germany

John M. Kane, MD
Vice President for Behavioral Health Services
Northwell Health
Chairman of Psychiatry
Zucker Hillside Hospital
Queens, New York
Chairman of Psychiatry
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York

For more programs in this series, visit:
https://bit.ly/3AhRXau

View Details

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the ongoing bipolar disorder research and developments expected to have an impact in the coming year. They elaborate on the various neurotransmitters being investigated and how this research might change the future of patient care. From investigating new mechanisms of action to increased uptake of more novel therapeutics such as esketamine and neuromodulation, there is a lot to look forward to. As they note in the podcast: It’s an exciting time to be in the field of brain science!

Presenters:
Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Vladimir Maletic MD
Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.

For more programs in this series, visit:
https://bit.ly/3ft1rYI

View Details

Get answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.

Presenters:

Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Charles DeBattista, DMH, MD
Chief
Depression Research Clinic
Director
Medical Student Education in Psychiatry
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, California

Stuart Isaacson, MD
Director
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida

Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Jonathan M. Meyer MD
Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Rajesh Pahwa, MD
Chief, Parkinson and Movement Disorder Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, Kansas

For more programs in this series, visit:
https://bit.ly/3Bg0oTv

View Details

In this episode, Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, shed light on the symptom improvement timeline in bipolar depression. This is a topic made more complex when factoring in individual patient characteristics and comorbidities, but the 2 experts have astute insights on how to tailor a management plan based on such factors. They cover symptom management and improvement from a variety of angles, including evaluating improvement in functionality and mood, guidance on follow-up and dose adjustment schedules, the utility of measurement-based care, and—of most importance—how to best communicate with and support a patient while they work towards remission and recovery.

Presenters:

Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.

For more programs in this series, visit:
https://bit.ly/3ft1rYI

View Details

In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia from identification to follow-up and ongoing management. They provide valuable insights on pharmacologic options to both consider and avoid to optimize outcomes in patients with tardive dyskinesia, including a focus on clinical strategies for use of VMAT2 inhibitors.

Presenters:

Robert O. Cotes, MD
Associate Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Jonathan M. Meyer, MD
Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

View Details

In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.

Presenters:

Diana O. Perkins, MD, MPH
Professor, Psychiatry
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Rajiv Tandon, MD
Emeritus Professor of Psychiatry
Department of Psychiatry
Western Michigan University Homer Stryker MD College of Medicine
Kalamazoo, Michigan

This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences.

For more programs in this series, visit:
https://bit.ly/3yOL8f7

View Details

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, share their thoughts on treatment strategies across the bipolar depression spectrum. They begin by talking about their stance on treating bipolar with comorbidities with a holistic vs stepwise approach and discuss what strategies they would consider for a patient not yet diagnosed with but who is at risk of developing bipolar depression. In addition, they discuss the concept of phase-specific treatment, considerations for medication-related adverse events, and the utility of adjunctive measures for managing bipolar depression.

Presenters:

Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Vladimir Maletic MD
Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.

For more programs in this series, visit:
https://bit.ly/3TClDqb

View Details

In this podcast episode on tardive dyskinesia (TD), Joseph P. McEvoy, MD, interviews Leslie, a patient who was diagnosed with TD 10 years ago. She describes her journey to an accurate diagnosis, the impact that TD has on her daily life, and her advice for patients and providers affected by TD.

Presenters:

Joseph P. McEvoy MD
Professor
Psychiatry and Health Behavior
Psychiatrist
Augusta University
Augusta, Georgia

Leslie

This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.

For more programs in this series, visit:
https://bit.ly/3dUCVi6

View Details

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the complexities of accurately diagnosing bipolar depression. Bipolar depression can be difficult to differentiate from other psychiatric conditions, such as unipolar depression, depression with mixed features, ADHD, PTSD, and anxiety. This differential is made more challenging in that patients with bipolar depression often have psychiatric comorbidities with overlapping symptomology. Listen as the 2 psychiatrists share their insights on how to act as detectives and weed through clues from current symptoms, past symptoms, and family history to reach an accurate diagnosis.

Presenters:

Greg W. Mattingly, MD
Associate Clinical Professor Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Vladimir Maletic MD
Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.

For more programs in this series, visit:
https://bit.ly/3TClDqb

View Details

Get answers to the questions that you and your colleagues have asked! In this episode, Charles DeBattista, MD, provides answers to audience questions that were submitted at 2 recent Psychiatry Update meetings. His thoughtful responses cover your questions on differential diagnosis, initiating pharmacotherapy, medication management, and more. Moderators Amber Hoberg, PMHNP, and Greg W. Mattingly, MD, provide complementary commentary throughout the Q&A session, adding interprofessional perspective to the activity.

Presenters:

Amber Hoberg, PMHNP
Nurse Practitioner
MorningStar Family Medicine
Floresville, Texas

Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.

For more programs in this series, visit:
https://bit.ly/3cX8eby

For physicians (MD, DO), psychiatry specialist NPs and PAs, pharmacists, social workers, and psychologists, register at:
https://bit.ly/3Q1WLWR
For NPs and PAs in primary care/other specialties, register at:
https://bit.ly/3Jf54Ma

View Details

In this first of 6 podcast episodes on tardive dyskinesia (TD), Drs Greg W. Mattingly and Jonathan M. Meyer have a discussion on identifying TD in clinical practice—including how to effectively screen patients during telehealth appointments. They cover who should be screened and how often, informal vs formal screening, and the valuable insight that family/caregiver reports can provide in the identification process. Additional conversation sheds light on differentiating TD from other movement disorders, including tics and tremors, and the role of primary care and other specialty providers in helping to identify TD. The experts round out the podcast with a focus on the impact of TD on both patient and caregiver quality of life—even mild TD can have an enormous influence over emotional, social, and mental well-being—bringing home the point that screening for and identifying TD early on is very important for patient outcomes.

Presenters:

Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Jonathan M. Meyer, MD
Voluntary Clinical Professor
Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.

For more programs in this series, visit:
https://bit.ly/3AhRXau

View Details

In this episode, Drs Greg W. Mattingly and Charles DeBattista have a conversation about the history and features of the bipolar spectrum. Because patients can present in mixed vignettes, diagnosis of bipolar depression can be challenging. The experts offer insight on when to hold a suspicion for bipolar depression, as well as common presentations they have seen over their years in clinical practice. The conversation then progresses to potential “triggers” of bipolar depression and culminates with a discussion of the current treatment paradigm for patients with bipolar depression: first- or second-generation antipsychotics.

Presenters:

Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.

For more programs in this series, visit:
https://bit.ly/3bPCiVH

View Details

In this episode, Diana Perkins, MD, MPH, and Martha Sajatovic, MD, discuss the impact of tardive dyskinesia on social and functional domains and the benefits of proper assessment and treatment of tardive dyskinesia in improving patient quality of life in these areas.

Presenters:

Diana Perkins, MD, MPH
Professor of Psychiatry
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Martha Sajatovic, MD
Professor of Psychiatry and Neurology
Departments of Psychiatry and Neurology
Case Western Reserve University School of Medicine
Cleveland, Ohio

Link to full program:
https://bit.ly/3GkJmUS

View Details

In this episode, Roger McIntyre, MD, FRCPC, and Sanjay Mathew, MD, discuss choosing the right treatment in bipolar depression. They review patient assessment and differential diagnosis for bipolar depression, describe various screening tools, examine evidence-based pharmacotherapies, consider the role of adjunctive antidepressants, neuromodulation, light therapy, and psychological treatments, and explore future directions in bipolar depression treatment.

Presenters:

Sanjay J. Mathew, MD
Professor and Vice Chair for Research
Psychiatry and Behavioral Sciences
Baylor College of Medicine
Houston, Texas

Link to full program:
https://bit.ly/3syJzh2

View Details

In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss who PCPs should screen for TD, adverse effects PCPs should put on their radar screen when monitoring patients on antipsychotics, how TD is different from parkinsonism, the use of anticholinergics, and which patients have an increased risk for TD when on antipsychotics.

Presenters:

Greg Mattingly, MD
Associate Clinical Professor
Psychiatry, Psychopharmacology
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

W. Clay Jackson, MD, DipTh
Assistant Professor of Clinical Family Medicine & Psychiatry
College of Medicine
University of Tennessee
Director
Palliative Care
West Cancer Center
Memphis, Tennessee

Link to full program:
https://bit.ly/2RM8hfM

View Details

In this episode, Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder. They review use of newer antidepressants (eg, vortioxetine, vilazodone) for bipolar depression despite lack of large, formal studies for that indication, the safety/efficacy of antidepressants for bipolar II vs bipolar I, antidepressant monotherapy in bipolar II depression, ketamine/esketamine for bipolar depression, and discuss the role for an antidepressant for bipolar depression in the absence of mixed features.

Podcast from Clinical Care Options (CCO) with Joseph Goldberg, MD, and Greg Mattingly, MD, on the role of antidepressants in bipolar disorder.

Presenters:

Joseph Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Link to full program:
https://bit.ly/3syJzh2

View Details

In this episode, Leslie Citrome, MD, MPH, and Manpreet K. Singh, MD, MS, discuss diagnosing unipolar vs bipolar depression. They review why it can be difficult to differentiate between unipolar and bipolar depression; which screening tools they employ, including the rapid mood screener (RMS); how to reduce chances of missing mania; and special tips for differentiating between major depressive disorder (MDD) and bipolar depression in children.

Presenters:

Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Manpreet K. Singh, MD, MS
Associate Professor of Psychiatry and Behavioral Sciences
Stanford University
Stanford, California

Link to full program:
https://bit.ly/3syJzh2

View Details

In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.

Presenters:

Greg Mattingly, MD
Associate Clinical Professor
Psychiatry, Psychopharmacology
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Link to full program:
https://bit.ly/2RM8hfM

View Details

In this episode, John M. Kane, MD, and Rebecca S. Roma, MD, discuss clinical assessment of extrapyramidal symptoms (EPS), antiparkinsonian drugs, and tardive dyskinesia (TD). They review differentiating between TD and EPS, identify tools for diagnosing TD, and provide some important clinical pearls and evidence-based reasons for choosing different medications for treating EPS and TD.

Presenters:

John M. Kane, MD
Professor and Chairman
Department of Psychiatry
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Glen Oaks, New York

Rebecca S. Roma, MD
Medical Director
REACH, LLC
Pittsburgh, Pennsylvania

Link to full program:
https://bit.ly/2RM8hfM

View Details

In this episode, Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss clinical assessment and diagnosis of tardive dyskinesia (TD). They review using the AIMS exam for identification of dyskinesia in patients in both the clinical setting and via telepsychiatry. They also review how often to perform the AIMS exam, how to assess the results, and why it is important.

Presenters:
Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Joseph P. McEvoy, MD
Professor
Psychiatry and Health Behavior
Psychiatrist
Augusta University
Augusta, Georgia

Link to full program:
https://bit.ly/2RM8hfM

View Details

In this episode, Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss tardive dyskinesia (TD), mood disorders, and antipsychotics. They review current clinical considerations and assessments, including whether antipsychotic prescriptions for mood disorders have increased, if patients with mood disorder are at higher risk for TD and why, and when and how to use an AIMS exam, even in telepsychiatry. They also review the evidence base for VMAT2 inhibitors in TD, what nonevidence-based treatments healthcare professionals should avoid, and how to choose between the 2 VMAT2 inhibitors.

Presenters:

Joseph Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Content based on an online CME program supported by an educational grant from Neurocrine Biosciences.

Link to full program:
https://bit.ly/2RM8hfM

CCO Neuroscience Podcast: Recent Episodes

Clinical Care Options